Tuesday, March 19, 2024

Newsletters

Events

Research

Career

Anti-Corruption Risks and Compliance Trends in the Pharmaceutical, Medical Device and Life Sciences Industries

0
When:
May 11, 2021 @ 1:00 pm – 2:00 pm
2021-05-11T13:00:00-04:00
2021-05-11T14:00:00-04:00
Contact:
Volkov Law

The U.S. Department of Justice, the Securities and Exchange Commission, and foreign law enforcement partners, continue to target global companies in the drug, device and life science industries for anti-corruption activities. Last year, despite the COVID-19 pandemic, the Justice Department and the SEC brought several significant enforcement actions against Novartis & Alcon, Herbalife, Alexion Pharmaceuticals, and Cardinal Health.

Blue Umbrella, a leading global technology company that delivers a suite of third-party risk management and compliance solutions, and Michael Volkov, Principal at The Volkov Law Group, are pleased to announce a risk and compliance focused webinar, Anti-Corruption Risks and Compliance Trends in the Pharmaceutical, Medical Device and Life Sciences Industries. Joining Mike Volkov on the webinar will be Brad Gates, SVP Global Client Development, from Blue Umbrella. Mike and Brad will address several important issues, including:

  • U.S. Department of Justice and SEC enforcement focus on global companies involved in drug, medical device and life science industries.
  • Understanding anti-corruption risks in foreign health care markets arising from interactions with health care officials, regulators, physicians and other medical staff.
  • Assessment of third-party risks relating to distributors in foreign markets and strategies to mitigate these risks.
  • Developing comprehensive strategies to enter or expand business in foreign markets designed to increase business opportunities while mitigating anti-corruption risks, including monitoring, testing, and review of business operations.

Free Registration

Free access to Events Calendar, Job Postings, Exiting Afghanistan, and Annual Review with 2 weeks free trial access to Newsletters